The DOI matches its Crossref record; 37 of the 43 references it cites were found in a registry or an index.
Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
Open accessPublished version of a preprint
Abstract
Purpose: Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer. We determined the extent to which these 4 alterations are coexistent in the same carcinoma, and their impact on patient outcome. Experimental Design: Pancreatic cancer patients who underwent an autopsy were studied (n = 79). Matched primary and metastasis tissues were evaluated for intragenic mutations in KRAS, CDKN2A, and TP53 and immunolabeled for CDKN2A, TP53, and SMAD4 protein products. The number of altered driver genes in each carcinoma was correlated to clinicopathologic features. Kaplan–Meier estimates were used to determine median disease free and overall survival, and a Cox proportional hazards model used to compare risk factors. Results: The number of genetically altered driver genes in a carcinoma was variable, with only 29 patients (37%) having an alteration in all 4 genes analyzed. The number of altered driver genes was significantly correlated with disease free survival (P = 0.008), overall survival (P = 0.041), and metastatic burden at autopsy (P = 0.002). On multivariate analysis, the number of driver gene alterations in a pancreatic carcinoma remained independently associated with overall survival (P = 0.046). Carcinomas with only 1 to 2 driver alterations were enriched for those patients with the longest survival (median 23 months, range 1 to 53). Conclusions: Determinations of the status of the 4 major driver genes in pancreatic cancer, and specifically the extent to which they are coexistent in an individual patients cancer, provides distinct information regarding disease progression and survival that is independent of clinical stage and treatment status. Clin Cancer Res; 18(22); 6339–47. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Coexistent alterations in CDKN2A, KRAS, TP53 and SMAD4 were observed in pancreatic cancer, with frequent loss of tumor suppressors like CDKN2A, ARID1A, APC and ID3 [26,44].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Self-citationCaldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Self-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Self-citationAguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 4×
“Furthermore, although genetically engineeredmousemodels indicate that the concomitant expression of thesemutated genes is crucial to progress to invasion and metastasis in PDACs (15–19), the extent to which the coexistence of 3 or more of these altered genes in the same PDAC influence thebiologic behavior and survival…”
BackgroundInfluential
Cited by
Sorted by citations
Items 201–280 of 280
Layfield, L. J., Zhang, T., & Esebua, M. (2022) · Diagnostic Cytopathology · doi:10.1002/dc.25005 · Cited by 4
He, J., Maurer, H. C., Holmstrom, S. R., Su, T., Ahmed, A., Hibshoosh, H. H., Chabot, J. A., Oberstein, P. E., Sepulveda, A. R., Genkinger, J. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/288779 · Cited by 4
Comprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race
Moheb, M. N. E., Cummins, K. C., Shen, C., Bitar, E. R., Kim, S. J., Mayhew, M. M., Zhang, H., Witt, R. G., Ruff, S. M., & Tsung, A. (2025) · Cancer Medicine · doi:10.1002/cam4.71346 · Cited by 3
Eslinger, C. R., Sonbol, M. B., George, B., Babiker, H., Borad, M. J., & Bekaii‐Saab, T. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559325 · Cited by 3
Shiroma, N., Arihiro, K., Oda, M., & Orita, M. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205002 · Cited by 3
Overview of Pancreatic Cancer Biology
Jain, A. G., Saleem, T., Kumar, R., Khetpal, N., Zafar, H., Rashid, M. U., Ali, S., Majeed, U., & Ahmad, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817661-0.00001-9 · Cited by 3
Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer
Clay, R., & Siddiqi, S. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00016-5 · Cited by 3
Argalácsová, S., Vočka, M., Petruzelka, L. B., Ryska, M., Záruba, P., Krška, Z., Frýba, V., Ulrych, J., Černý, V., Tůma, T., et al. (2023) · Neoplasma · doi:10.4149/neo_2023_230409n193 · Cited by 3
Barreto, S. G. (2018) · Springer eBooks · doi:10.1007/978-981-10-8755-4_16 · Cited by 3
Pathobiology of pancreatic cancer: implications on therapy
Regel, I., Hausmann, S., Benitz, S., Esposito, I., & Kleeff, J. H. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1129276 · Cited by 3
Damanakis, A. I., Gebauer, F., & Bruns, C. J. (2020) · Der Chirurg · doi:10.1007/s00104-020-01172-0 · Cited by 3
Koya, T., Niida, Y., Togi, M., Yoshida, K., Sakamoto, T., Ura, H., Togi, S., Kato, T., Yamada, S., Sugiyama, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012177 · Cited by 3
Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype.
Hu, B. R., Fairey, A., Madhav, A., Yang, D., Li, M., Groshen, S. G., Stephens, C. L., Kim, P., Virk, N., Wang, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.7_suppl.29 · Cited by 3
Does biology determine survival in pancreatic cancer?
Barreto, S. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0706 · Cited by 3
Haan, D., Bergamaschi, A., Guler, G. D., Friedl, V., Ning, Y., Reggiardo, R. E., Kesling, M., Collins, M., Gibb, B., Pitea, A., et al. (2021) · medRxiv · doi:10.1101/2021.12.27.21268450 · Cited by 3
Wenric, S., Davison, J. M., Guittar, J. L., Mayhew, G. M., Beebe, K. D., Wang, Y. E., Iyer, A. A., Kang, H. P., Milburn, M. V., Chung, V. M., et al. (2023) · medRxiv · doi:10.1101/2023.02.23.23286356 · Cited by 2
Monga, J., Ghosh, R., Guddeti, R. K., Chitale, D. A., Khan, G. N., & Ghosh, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387535 · Cited by 2
Resection for pancreatic cancer metastases contributes to survival
Sato, H., Sasajima, J., Okada, T., Hayashi, A., Kawabata, H., Goto, T., Koizumi, K., Tamamura, N., Tanabe, H., Fujiya, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000020564 · Cited by 3
Asplund, E., Bergqvist, M., Krook, M., & Löhr, M. J. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2198057 · Cited by 2
Karimi, E., Kalaki, N. S., & Akrami, S. M. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101921 · Cited by 2
Koido, S., Taguchi, J., Shimabuku, M., Bito, T., Morimoto, S., Oji, Y., Oka, Y., Ito, M., Shimizu, Y., Ito, Z., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011426 · Cited by 2
Neuregulin Signaling in the Tumor Microenvironment
Jia, R., Zhao, H., & Wang, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_1 · Cited by 1
The Present and Future of Screening in Breast Cancer Prevention
Russo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-72815-1_9 · Cited by 2
Regalla, D. K. R., Deep, O., & Paluri, R. K. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-79 · Cited by 2
Cancer Metastasis: Tracking and Attacking a Moving Target
Rodenhiser, D. I., & Chambers, A. F. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_1 · Cited by 2
Mao, L., Li, A., Zhao, X., Hou, S., Lu, S., Mou, Y., Liu, X., Cai, S., Cao, D., & Tian, B. (2020) · Pancreas · doi:10.1097/mpa.0000000000001522 · Cited by 2
Improving Survival of Pancreatic Cancer. What Have We Learnt?
Singh, T., & Chaudhary, A. (2015) · Indian Journal of Surgery · doi:10.1007/s12262-015-1368-7 · Cited by 1
Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma
Kantheti, H. S., Hale, M. A., Choudhuri, S. P., Huang, H., Wang, X., Zolghadri, Y., Innamorati, G., Manikonda, S. P. R., Reddy, N. R., Reddy, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126619 · Cited by 1
Zhang, X., Wong, W., Cho, H. S., Yang, D., Dixon, G., Luo, R., Liu, D., Torre, D., Umeda, S., Gonzãlez, F., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.04.012 · Cited by 2
Self-citationHenstridge, A. Z., Azorsa, P. A., Arya, N., Elhossiny, A. M., Kadiyala, P., Goldwasser, M., Branch, G., Sahai, V., Peterson, N., Machicado, J. D., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-0823 · Cited by 1
Zauber, P., Marotta, S. P., & Sabbath‐Solitare, M. (2013) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2013.38059 · Cited by 1
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_74 · Cited by 1
Clinical sequencing of pancreatic cancer in clinical practice
Hayashi, H. (2018) · Suizo · doi:10.2958/suizo.33.915 · Cited by 1
A preclinical mouse model of hepatic metastasis to instruct effective treatment modalities
Pocaterra, A., Citro, A., Gnasso, C., Canu, T., Tosi, A., Rosato, A., Esposito, A., Piemonti, L., & Mondino, A. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.07.008 · Cited by 1
Unusually high levels of serum p53 antibody in recurrent gastric cancer
Kunizaki, M., Hamasaki, K., Wakata, K., Hidaka, S., Nagayasu, T., & Kinoshita, Y. (2017) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-017-0780-x · Cited by 1
Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Li, Z., Li, W., Dong, Y., & Sun, X. (2019) · Clinical Cancer Drugs · doi:10.2174/2212697x06666190328180331 · Cited by 1
The Hallmarks of Pancreatic Cancer
Damanakis, A. I., Gebauer, F., Popp, F., & Bruns, C. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_14 · Cited by 2
Pereyra, J., & Galiana, J. M. D. (2021) · Cirugía del Uruguay/Cirugía del Uruguay · doi:10.31837/relatos/8 · Cited by 1
Langzeitverlauf nach operativer Tumorentfernung und Chemotherapie des duktalen Pankreaskarzinoms
Strobel, O., & Werner, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-37964-2_79 · Cited by 1
Pancreatic Cancer Experimental and Clinical Studies
Ljungman, D. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Findet die molekulare Diagnostik Einzug in die Pankreaspathologie?
Sipos, B., & Sperveslage, J. (2013) · Der Pathologe · doi:10.1007/s00292-013-1865-z
Pancreatic adenocarcinoma: current treatment approaches and controversies
Herman, J. M. (2013) · Journal of Radiation Oncology · doi:10.1007/s13566-013-0126-3
Self-citationPancreatic cancer: molecular genomics and clinical applications
Yachida, S., & Takai, E. (2016) · Suizo · doi:10.2958/suizo.31.10
Self-citationEvaluation of KRAS Mutational Status in Pancreatic Ductal Adenocarcinoma
Năstase, A., Dima, S., Heng, H. L., Young, C. C., Myint, S. S., Loh, J. L., Ong, C. K., Teh, B. T., Herlea, V., Duda, D. G., et al. (2016) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-21-2-81
Genomic Instability: The Pivotal Role of Mutant P53 in Human Cancers
Agostino, S. D., & Blandino, G. (2016) · Chemotherapy Open access · doi:10.4172/2167-7700.1000191
Klassifikation und malignes Potenzial der zystischen Pankreastumoren
Rüschhoff, K., & Medizin, S. (2015)
A NOVEL ROLE FOR SMAD6 IN THE BIOLOGY OF PANCREATIC CANCER
Brosnan‐Cashman, J. A. (2014)
Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma
Alhenc-Gelas, M., Cohen, R., Cervera, P., Vaillant, J., & André, T. (2019) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2019/8598635
Pathologie und molekulare Marker
Tannapfel, A., & Munding, J. B. (2020) · Im Focus Onkologie · doi:10.1007/s15015-020-2350-1
Gastrointestinal, Hepatobiliary, and Pancreatic Tumors
Mohammad, M. K., & Chen, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-73227-1_8
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_74-1
Masugi, Y., Takamatsu, M., Tanaka, M. H., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197932
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2023) · doi:10.1158/1940-6207.c.6547127.v1
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2023) · doi:10.1158/1940-6207.c.6547127
Caracterización molecular de los tumores de páncreas y vías biliares
Barroso, G., García Carbonero, R., & Jarchum, G. D. (2023) · Methodo Investigación Aplicada a las Ciencias Biológicas · doi:10.22529/me.2023.8(2)03
Hepatic Macrophage Migration Inhibitory Factor Promotes Pancreatic Cancer Liver Metastasis in NAFLDPreprint
Yu, Q., Song, H., Zhu, L., Shi, X.-Y., Wang, H., Wang, Y.-L., Gong, R., Cui, J.-F., Yang, X., Wang, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.02.595997
Kawabata, H., Yuzawa, S., Takahashi, K., Tanino, M. A., & Mizukami, Y. (2024) · Suizo · doi:10.2958/suizo.39.316
Shimizu, H., Suzuki, R., Asama, H., Sugimoto, M., Sato, K., Ohira, R., Kametaka, A., Nakamura, J., Kato, T., Yanagita, T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5444557/v1
Marin, A. M., Timoner, B. E., Araújo, D. D., Uno, M., Alves, M. J. F., Chammas, R. J., Namur, G. N., Wosniaki, D. K., Canzian, F., Blanes, L., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5850874/v1
Islam, S. S., Tushar, M. M. H., Sarkar, B., Moni, R., Zohora, U. S., & Rahman, M. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.26.650766
The CancerenD24: A Novel Blood Test That Can Prevent Colorectal Cancer
Shapira, S., Yaakobi, H., Kazanov, D., Motlaq, M., Galazan, L., Grenshpon, R., Bruck, H., Deutsch, N., Deutsch, L., & Arber, N. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100757
Spoto, F., Robertis, R. D., Cardobi, N., Garofano, A., Messineo, L., Lucin, E., Milella, M., & D’Onofrio, M. (2025) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01627-y
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Li, M., Gao, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14956007
Luan, H., He, Y., Zhang, T., Su, Y., & Zhou, L. (2022) · Figshare · doi:10.6084/m9.figshare.19669952
Marin, A. M., Timoner, B. E., Araújo, D. D., Uno, M., Alves, M. J. F., Chammas, R. J., Namur, G. N., Wosniaki, D. K., Canzian, F., Blanes, L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-42403-4
Zhang, X., Wong, W. D., Cho, H., Yang, D., Dixon, G., Luo, R., Liu, D., Torre, D., Umeda, S., Gonzãlez, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.09.710586
Self-citationYumoto, S., Hayashi, H., Takematsu, T., Tanizaki, T., Sakoh, T., Ogawa, D., Uemura, N., Matsumoto, T., Kitano, Y., Nakagawa, S., et al. (2026) · Pancreas · doi:10.1097/mpa.0000000000002641
Duconseil, P. (2018) · theses.fr (ABES) · doi:10.70675/d5d8f2c6z9767z4f2fzb527zcdd6fa12bcbf
Elaborating novel and effective treatment for pancreatic cancer
Lan, W. (2020) · theses.fr (ABES) · doi:10.70675/f34e035dzcf8bz4855z91edz547ce2ab2ebd
Chang, E., & Shi, J. (2026) · Cells · doi:10.3390/cells15090837
Watanabe, F., Suzuki, K., Hasebe, R., Mizusawa, Y., Aizawa, H., Abe, I., Endo, Y., Ichida, K., Inoue, K., Noda, H., et al. (2026) · Pancreas · doi:10.1097/mpa.0000000000002650
Pancreatic cancer and its association with abdominal pain
Tarasiuk, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41638-5.00011-9
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
Jung, E., Jeong, H.-C., & Lee, K.-R. (2026) · Organoid · doi:10.51335/organoid.2026.6.e9
Choi, Y., Lee, E. J., Oh, D. H., Kim, H., Woo, S. M., Chun, J. W., & Kong, S. (2026) · Organoid · doi:10.51335/organoid.2026.6.e8
CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer
Rocco, M. A., Kirvaitytė, M., Lencioni, G., Mariani, S., McDonnell, L. A., Hussein, M., & Giovannetti, E. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218851
Integrated driver gene-based survival prediction in resected pancreatic cancer
Li, Z., Campbell, B. A., Molin, M. D., Song, Y., McPhaul, T. J., Zhang, S., Cameron, J. L., Lin, M.-T., Hruban, R. H., Shubert, C. R., et al. (2026) · British journal of surgery · doi:10.1093/bjs/znag123
Self-citation
Metadata
- Authors
- Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., Hruban, R. H., Klein, A. P., Jones, S., Velculescu, V., Wolfgang, C. L., & Iacobuzio-Donahue, C. A.
- Affiliations
- Kurume University (JP)
- Authors' Affiliations: Departments of 1Pathology, 2Oncology, 3Surgery, and 4Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, 5The Lugwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Medical Institutions, Baltimore, Maryland; 6National Cancer Center Research Institute, Tokyo; and 7Kurume University School of Medicine, Kurume, Fukuoka, Japan
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-11-14
- Volume
- 18
- Issue
- 22
- Pages
- 6339-6347
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3500447
- OpenAlex
- W2155563954
- Cited by
- 280
- References
- 43
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 17 · 2023: 22 · 2022: 27 · 2021: 33 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 23 · 2016: 15 · 2015: 22 · 2014: 15 · 2013: 12
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- Japan Society for the Promotion of Science (23390326, 24659612)
- National Cancer Institute (CA-101955, P20CA101955, R01CA140599, P50CA101955, R01-CA121113, CA-121113, CA140599, P50CA062924, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, driver gene alterations, KRAS, CDKN2A, TP53, SMAD4, long-term survival, disease-free survival, metastatic burden, prognostic factors, autopsy tissue
- MeSH terms
- Aged, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Proto-Oncogene Proteins, Risk Factors, Proportional Hazards Models, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Survivors, Disease-Free Survival, ras Proteins, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Burden, Smad4 Protein, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
